Full-Time

Director – Tax Reporting & Technology

Posted on 12/26/2025

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Remote in UK

Remote

Category
Accounting (1)
Required Skills
SAP Products
Alteryx
Oracle
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Requires substantial experience in the international tax function for U.S. based multinational companies with responsibility for ASC 740 reporting functions for the international subsidiaries of U.S. based multinational companies.
  • Experience in working with IT departments in the successful implementation of tax reporting requirements of accounting and tax software systems.
  • Requires an undergraduate degree and admission as a CPA, Chartered Accountant, or the equivalent.
  • Demonstrated track record of successfully managing corporate tax reporting in major international tax jurisdictions for the international subsidiaries of U.S. based multinational companies.
  • Requires substantial experience and knowledge of U.S. tax laws and regulations applicable to the international operations of U.S. based multinational companies, including a working knowledge of the provisions of the Tax Cuts & Jobs Act of 2017, e.g. GILTI.
  • Demonstrates high levels of energy, enthusiasm, dedication, and strong work ethic and the ability to communicate effectively both orally and in writing.
  • Strong leadership and interpersonal skills and the ability to collaborate with others.
  • Strong mathematical, analytical, organizational and presentation skills.
  • Ability to navigate ERP systems or financial reporting tools (e.g. Oracle, SAP, COGNOS, TRCS, Alteryx).
Responsibilities
  • Directs the company’s global non-U.S. tax accounting and reporting processes and systems to ensure that all international affiliates have adopted and implemented financial accounting procedures and systems to ensure accurate, efficient and timely reporting of quarterly and annual income tax expense in accordance with US GAAP, ASC 740 and applicable Company accounting policies and procedures.
  • Are in full compliance with the company’s Sarbanes Oxley key internal controls and procedures including deferred tax liabilities and reserves related to Accounting for Income Taxes.
  • Work with local affiliates to ensure that local reporting requirements are met, including oversight to ensure compliance software sufficiently meets reporting requirements.
  • Manages and enhances the company’s tax technology reporting solutions to continuously improve the efficiency, timeliness and accuracy of global reporting of income tax expense, including integration of the provision system with the company’s Financial Planning and ERP systems.
  • Develops processes and models to support SVP Tax, Controller and CFO in analyzing the cash tax and effective tax rate impacts of proposed legislation, M&A transactions, discrete events, jurisdictional audits and various planning scenarios.
  • Communicates in general business language complex tax and ASC 740 calculations to non-tax business executives verbally and via Excel and PowerPoint, including regularly liaising with company finance, accounting and FP&A personnel regarding projected effective tax rates, cash taxes and income tax disclosures.
  • Assists International Tax team to develop processes and models to support analyzing the cash tax and effective tax rate impacts of proposed legislation, M&A transactions, discrete events, jurisdictional audits and various planning scenarios.
  • Researches and stays abreast of accounting for income tax impacts of legislative changes in all Cencora companies.
  • Perform related duties as assigned.
Desired Qualifications
  • Advanced Excel skills (including PowerQuery).
  • Knowledge of utilizing a broader suite of tools within Office365, and/or knowledge of automation tools.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE